drugset / Trial / NCT04409925
DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)
Phase 1
Completed
15 enrolled
McGill University Health Centre/Research Institute of the McGill University Health Centre
Exactis Innovation · collabHamilton Health Sciences Corporation · collabHoffmann-La Roche · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot study to investigate the safety and feasibility of rhDNase1 and its impact on neutrophil extracellular traps (NETs) in COVID-19 infected patients.
Timeline
- Start
- 2020-12-25
- Primary completion
- 2021-04-01
- Completion
- 2021-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dornase alfa | Protein / enzyme biologic | 2.5 mg | Inhaled |